Alvotech (ALVO) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

18/25

Growth 5 Margin 3 Expansion 5 Platform 1 Financial 4

latest quarter score

Earnings Reports

18
Alvotech (ALVO) Q2 2026: Manufacturing Recovery and Broadening Biosimilar Portfolio Set Stage for Growth
August 26, 2026
15
Alvotech (ALVO) Q1 2026: Product Revenue Down 20% as Facility Upgrades Set Stage for 2027 Growth
May 07, 2026
18
Alvotech (ALVO) Q4 2025: Licensing Revenues Boost Gross Margin to 66% Amid U.S. Regulatory Reset
March 19, 2026
13
Alvotech (ALVO) Q3 2025: FDA Delay Shifts $30M+ Licensing Revenue Into 2026, Margin Recovery Hinges on Launch Execution
November 13, 2025
18
Alvotech (ALVO) Q2 2025: Product Revenue Soars 77% as Margin Focus Drives Biosimilar Expansion
August 14, 2025
22
Alvotech (ALVO) Q1 2025: Raises Revenue Guidance to $700M as Biosimilar Launches Accelerate
July 06, 2025
23
Alvotech (ALVO) Q4 2024: Biosimilar Launches Drive 427% Revenue Surge and Pipeline Expansion
March 27, 2025
Alvotech (ALVO) Q2 2024: U.S. Humira Order Book Rises 30% as Biosimilar Scale Drives EBITDA Inflection
August 16, 2024
Alvotech (ALVO) Q1 2024: 1 Million Humira Biosimilar Orders Signal Inflection in Commercial Scale
May 22, 2024
Alvotech (ALVO) Q4 2023: 3-4x Revenue Surge Forecast on Global Biosimilar Launches and Milestones
March 21, 2024
Alvotech (ALVO) Q1 2023: Revenue Jumps 16x on Biosimilar Launches, U.S. Approval Uncertainty Persists
May 19, 2023
Alvotech (ALVO) Q4 2022: Revenue Doubles as U.S. Humira Biosimilar Launch Nears
March 02, 2023

Browse all companies